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Background: The mechanism of liver fibrosis in 
Niemann Pick disease (NPD) is unknown. 
Results: The loss of ASMase stimulates cathepsin 
B (CtsB) activation promoting liver fibrosis. 
Conclusion: CtsB contributes to the hepatic 
phenotype of NPD. 
Significance: CtsB may be a novel therapeutic 
target to treat liver disease in NPD. 
 
SUMMARY 
Niemann Pick disease (NPD) is a 
lysosomal storage disease caused by the loss of 
acid sphingomyelinase (ASMase) that features 
neurodegeneration and liver disease. Since 
ASMase knockout mice models NPD and our 
previous findings revealed that ASMase 
activates cathepsins B/D (CtsB/D), our aim was 
to investigate the expression and processing of 
CtsB/D in hepatic stellate cells (HSC) from 
ASMase null mice and their role in liver 
fibrosis. Surprisingly, HSC from ASMase 
knockout mice exhibit increased basal level and 
activity of CtsB as well as its in vitro processing 
in culture, paralleling the enhanced expression 
of fibrogenic markers α-SMA (alpha-smooth 
muscle actin), TGF-β and Col1A1 (pro-
collagen-α1(I)). Moreover, pharmacological 
inhibition of CtsB blunted the expression of α-
SMA, Col1A1 and proliferation of HSC cells 
from ASMase knockout mice. Consistent with 
the enhanced activation of CtsB in HSC from 
ASMase null mice, the in vivo liver fibrosis 
induced by chronic treatment with CCl4 
increased in ASMase null compared to wild-
type mice, an effect that was reduced upon CtsB 
inhibition. In addition to liver, the enhanced 
proteolytic processing of CtsB was also 
observed in brain and lung of ASMase 
knockout mice, suggesting that the 
overexpression of CtsB may underlie the 
phenotype of NPD. Thus, these findings reveal a 
functional relationship between ASMase and 
CtsB and that the ablation of ASMase leads to 
the enhanced processing and activation of CtsB. 
Therefore, targeting CtsB may be of relevance 
in the treatment of liver fibrosis in patients with 
NPD. 
Acid sphingomyelinase (ASMase; EC 
3.2.1.14) is a member of an enzyme family that 
catalyzes the breakdown of sphingomyelin into 
ceramide. ASMase works optimally at acidic pH 
and is mainly located in the endo/lysosomal 
compartments (1). Besides its important 
participation as key structural component of 
biological membranes, ceramide is recognized as a 
critical second messenger, which regulates many 
cell functions (2,3). In particular, ceramide 
generation by ASMase is rapid and transient and 
plays a proapoptotic role in response to many 
different stimuli (2,3). ASMase derives from a 
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proinactive form whose proteolytic processing 
within the C terminal leads to the maturation of an 
endosomal/lysosomal Zn2+-independent form and a 
Zn2+-dependent secretory isoenzyme (4). 
Niemann-Pick disease (NPD) is a rare 
lysosomal storage disorder caused by recessive 
mutations on SPMD1 gene encoding ASMase 
(5,6). NPD type A and B, the most common 
subtypes of this disease, share features such as the 
accumulation of sphingomyelin, cholesterol, 
glycosphingolipids, and bis (monoacylglycero)-
phosphate in the visceral organs such as liver, 
spleen and lung. The subsequent formation of 
foam cells is the main cause of 
hepatosplenomegaly, pulmonary insufficiency and 
cardiovascular disease (6). NPD type A patients 
typically exhibit almost a total loss of ASMase 
activity and suffer neurological degeneration that 
reduces their lifespan to about 3 years of age. NPD 
type B patients, however, frequently survive into 
adulthood and exhibit a milder phenotype with 
little or no neurodegeneration depending on the 
remaining percentage of ASMase activity (7). 
Despite the generation of the ASMase knockout 
mice as an animal model of NPD type A exhibiting 
neurological degeneration, hepatosplenomegaly 
and lung dysfunction (8,9), little progress has been 
made in NPD treatment.  
Cathepsins are a family of lysosomal 
proteases whose participation in different 
pathologies such as liver fibrosis (10), 
atherosclerosis (11), Alzheimer (12) and cancer 
(13,14) has been reported in the past years. In 
particular, cathepsin B (CtsB) and cathepsin D 
(CtsD) have been implicated in signaling pathways 
of apoptosis (15,16) and liver fibrosis (17). 
Moreover, recent studies have revealed that 
ASMase controls the proteolytic processing of 
CtsB/D, and hence ASMase downregulation 
impairs CtsB/D processing resulting in decreased 
hepatic stellate cell (HSC) activation in vitro and 
lower in vivo fibrogenesis (17). However, since 
many cathepsins are proteolytically processed by 
other members of the family, and due to the 
hierarchical relationship between ASMase and 
CtsB/D (17), we postulated that the complete loss 
of ASMase may lead to an adaptive overexpression 
of CtsB/D. To test this hypothesis we addressed 
the regulation of CtsB/D in ASMase knockout 
mice and examined the activation of HSC in vitro 
and liver fibrosis in vivo as a potential contributory 
mechanism for enhanced liver disease observed in 
many NPD patients (18-21). Moreover, since NPD 
phenotype is not restricted to liver, we addressed 
the regulation of CtsB/D in other commonly 
affected organs of ASMase knockout mice. Our 
findings revealed an increased proteolytic 
processing of CtsB/D in HSC from ASMase null 
mice and that the pharmacological inhibition of 
CtsB prevents in vitro HSC activation and 
proliferation. Consequently, ASMase knockout 
mice exhibit increased in vivo liver fibrosis 
induced by CCl4 challenge, which is reduced upon 
CtsB inhibition. Similar findings regarding 
enhanced basal levels and increased processing of 
CtSB/D were observed in brain and lung from 
ASMase knockout mice. Thus, these findings 
imply that the therapeutic targeting of CtsB may be 
of relevance in the treatment of liver fibrosis in 
patients with NPD. 
 
 
EXPERIMENTAL PROCEDURES 
Reagents. DMEM, Trypsin-EDTA, 
Penicillin-streptomycin, TRIzol, FBS, HistoGrip, 
Optimem, were from Invitrogen (Paisley, United 
Kingdom). All tissue culture ware was from Nunc 
(Roskilde, Denmark). DAKO Biotin Blocking 
System, peroxidase substrate (DAB), peroxidase 
buffer, and hematoxylin were from DAKO 
(Glostrup, Denmark). Aquatex was from Merck 
(Darmstadt, Germany). The ABC kit was from 
Vecstain (Burlingame, CA). PDGF-BB was from 
PeProtechEC (London, United Kingdom). 
Proteinase inhibitors were from Roche (Madrid, 
Spain). iScript™ One-Step reverse transcription 
(RT)–PCR Kit with SYBR® Green was from 
BioRad (Hercules, CA). ECL western blotting 
substrate was from Pierce (Thermo Fisher 
Scientific, Rockford, IL). Ca074Me were from 
Sigma-Aldrich (St. Louis, MO), and, unless 
otherwise stated, all other reagents were also from 
Sigma-Aldrich (St. Louis, MO). 
Antibodies. We used the following primary 
antibodies, rabbit polyclonal anti-cathepsin B 
(Cat#06-480) and rabbit polyclonal anti-Col1A1 
(Cat#AB765P), Millipore, Billerica, MA). Goat 
polyclonal anti-cathepsin D (Cat#sc-6486), mouse 
monoclonal pan-cathepsin (Cat#sc-365614) (Santa 
Cruz Biotechnology, Heidelberg, Germany). 
Rabbit polyclonal anti-α-SMA (Cat#ab5694), 
rabbit polyclonal anti-myeloperoxidase 
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(Cat#ab15484), rat monoclonal anti-LAMP-2 
(Cat#ab13524) (Abcam, Cambridge, United 
Kingdom). mAb anti-α-SMA (Cat#A2547), mAb 
anti-β-actin (Cat#A1978) and ECL-peroxidase 
labeled anti-mouse (Cat#A9044), anti-rabbit 
(Cat#A0545), anti-goat (Cat#A5420) (Sigma-
Aldrich, St. Louis, MO), anti-rat (Cat#819520, 
Invitrogen). Rabbit polyclonal anti-HSP70 (Enzo 
LifeSciences, Farmingdale, New York). Rabbit 
polyclonal anti-LC3B (Cat#2775) (Cell Signaling 
Technology, Inc., Danvers, Massachusetts). Alexa 
Fluor 488 goat anti-rat (Cat#A11006), Alexa Fluor 
594 rabbit anti-goat (Cat#A11080), Alexa Fluor 
647 goat ant-rabbit (Cat#A21245) (Invitrogen, 
Paisley, United Kingdom). Biotinilated labeled 
anti-rabbit was from BD-PharmigenTM. 
Animals and HSCs isolation. Wild-type 
and ASMase knockout mice (male, 8-10 weeks old 
littermates) (C57BL/6 strain) were obtained by 
propagation of heterozygous breeding pairs (a 
generous gift from R. Kolesnick, Memorial Sloan-
Kettering Cancer Center, New York, USA; and E. 
Gulbins, University of Duisburg-Essen, Germany) 
and genotyped as described previously (22). All 
animals received humane care according to the 
criteria outlined in the "Guide for the Care and Use 
of Laboratory Animals" published by NIH. HSCs 
were isolated by perfusion with collagenase-
pronase and cultured as previously described (10). 
Culture purity, assessed routinely by retinoid 
autofluorescence at 350nm, was >95%.  Lack of 
staining for F4/80 confirmed absence of Kupffer 
cells. Cells were cultured in DMEM supplemented 
with 10% FBS, and antibiotics at 37ºC in a 
humidified atmosphere of 95% air and 5% CO2. 
In vivo liver fibrogenesis. Wild-type or 
ASMase KO mice were treated with CCl4 at a dose 
of 5 µL (10% CCl4 in corn oil)/g body weight, by 
intraperitoneal injection twice a week for 4 weeks. 
Control animals received corn oil alone. Ca074Me 
(Sigma-Aldrich) was administered 30 minutes 
before CCl4, for the last three week of the study. 
Ca074Me was given intraperitoneally in a dosage 
according to CtsB expression in liver (0.25mg- 
1.0mg/mice). 
ASMase activity. ASMase activity from 
cellular extracts was determined using a 
fluorescent sphingomyelin analog (NBD C6- 
sphingomyelin). Samples were incubated 60 min at 
37ºC in incubation buffer containing 10 µmol/L 
NBD C6-sphingomyelin (250 mmol/L sodium 
acetate, 0.1% triton X-100 pH 5.0). Lipids were 
extracted, dried under N2, and separated by TLC 
(chloroform: methanol: 20% NH4OH; 70:30:5, 
v/v). NBD-ceramide was visualized under UV 
light, and images acquired and analyzed using a 
Gel Doc XR System with Quantity One software 
(Biorad, Hercules, CA). Furthermore, ASMase 
activity in tissue lysates was performed as 
described (17). 
CtsB and CtsD activities. CtsB activity 
was assayed fluorimetrically with Z-Arg-Arg-7-
amido-4-methylcoumarin hydrochloride (60 
µmol/L) at pH 7.4 and 37°C as previously 
described (10). Cathepsin D was assayed using a 
“Cathepsin D Activity Assay Kit” (Cat#ab65302, 
Abcam) following the manufacturer instructions. 
Results were expressed as cathepsin activity (slope 
of fluorescence emission after 40 minutes) per 
milligram of protein. 
SDS-PAGE and immunoblot analysis. Cell 
lysates were prepared in RIPA buffer (50 mmol/L 
Tris·HCl, pH 8, 150 mmol/L NaCl, 1% Nonidet P-
40, 0.1% SDS, 1% Triton X-100 plus proteinase 
inhibitors). Protein concentration was determined 
by Bradford assay, and samples containing 10 to 
30µg were separated by 8-10% SDS-PAGE. 
Proteins were transferred to nitrocellulose 
membranes. After membranes were blocked in 8% 
nonfat milk or 5% BSA in 20 mmol/L Tris-HCl, 
150 mmol/L NaCl, and 0.05% Tween-20 for 1h at 
room temperature, the membranes were incubated 
overnight at 4°C with different primary antibodies 
and developed with ECL-peroxidase system. 
             HSC proliferation. Proliferation was 
estimated as the amount of [3H] thymidine 
incorporated into TCA-precipitable material as 
previously described (17).  
Hydroxyproline content. Hepatic 
hydroxyproline content was determined by the 
method of Jamall et al. (23), as previously 
described (10). Data were normalized to wet liver 
weight. 
RNA isolation and real time RT-PCR of 
mouse samples. Total RNA was isolated from 
hepatic stellate cells with TRIzol reagent. Real-
time RT-PCR was performed with iScript™ One-
Step reverse transcription-PCR Kit with SYBR® 
Green following the manufacturer's instructions. 
The primers sequences used were: mouse α-SMA, 
Fw 5’-ACTACTGCCGAGCGTGAGAT-3’ and 
Rv 5’-AAGGTAGACAGCGAAGCCAA -3’ 
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(GenBank Accession# NM_007392); mouse TGF-
β, Fw 5’-GTCAGACATTCGGGAAGCAG-3’ and 
Rv 5’- GCGTATCAGTGGGGGTCA-3’ 
(GenBank Accession# NM_011577); mouse 
Col1A1, Fw: 5’-
ACTTCACTTCCTGCCTCAG-3’ and Rv: 5’-
TGACTCAGGCTCTTGAGGGT-3’ (GenBank 
Accession# NM_007742); mouse β-actin, Fw: 5’-
GACGGCCAGGTCATCACTAT-3’and Rv: 5’-
CGGATGTCAACGTCACACTT -3’ (GenBank 
Accession# NM_007393). 
Immunohistochemical staining. Paraffin 
molds containing liver sections were cut into 5-µm 
sections and mounted on HistoGrip coated slides. 
The sections were deparaffinized in xylene and 
dehydrated in graded alcohol series. Endogenous 
peroxidase (3% H2O2) and avidin and biotin were 
blocked. Slides were incubated with primary 
antibody overnight in a wet chamber at 4ºC. After 
rinsing with PBS 1X, the slides were incubated 
with a biotinylated antibody for 45 minutes in a 
wet chamber, and developed with the ABC Kit 
with peroxidase substrate (DAB) and peroxidase 
buffer. After rinsing the slides with tap water they 
were counterstained with hematoxylin and 
mounted with Aquatex.  
H&E and Sirius Red staining. Livers were 
fixed, included in paraffin, and sections of 7-µm 
were routinely stained with H&E, Periodic Acid 
Schiff (PAS), Nissl staining or with a 0.1% Sirius 
Red-picric solution following standard procedures. 
Statistical analyses. All images display 
representative data from at least 3 independent 
observations. The experiments were repeated at 
least three times. The statistical significance of 
differences was performed using the unpaired, 
non-parametric Student’s t test. 
 
RESULTS 
HSCs from ASMase knockout mice exhibit 
increased CtsB/D processing and fibrogenic 
potential. Given the functional relationship 
between ASMase and cathepsins recently reported 
in liver fibrosis (17), we analyzed the expression of 
CtsB and CtsD in HSCs from ASMase-/- mice. 
HSCs were isolated and cultured in plastic in order 
to follow their activation process in vitro from 
quiescents HSC to myofibroblasts like cells 
responsible of the fiber deposition. As shown in 
Fig. 1A we observed an up-regulation of CtsB and 
CtsD expression and processing compared to wild-
type HSCs. In particular, CtsB expression was 
remarkably induced, as shown by the enhanced 
activity of CtsB in ASMase-/- HSCs compared to 
wild-type HSCs (Fig. 1B). Kinetic analyses 
revealed enhanced expression of CtsB/D at the 
early phase in the activation of HSC (Fig. 1A, 1B). 
Genetic deficiency of ASMase resulted also in 
elevated expression of the activation markers α-
SMA and pro-collagen-α1(I) (Col1A1) at the 
protein (Fig. 1A) and mRNA level (Fig. 1C and 
1D), which was further accompanied by 
overexpression of other markers of HSC activation 
such as transforming growth factor-β (TGF-β) 
(Fig. 1E). Considering the difference in fold 
increase of mRNA levels for α-SMA and Col1A1, 
the corresponding increase at the protein level at 
day 8 of culture was more apparent for Col1A1 
than for α-SMA. In parallel with these 
observations, the proliferation rate of HSC from 
day 2 after isolation to day 8 of culture was 
significantly increased in ASMase-/- HSCs 
compared to wild-type HSCs (Fig. 1F). Thus, 
HSCs from ASMase-/- mice exhibit increased 
fibrogenic potential, which correlated with 
enhanced CtsB/D levels and processing.  
CtsB inhibition diminishes activation of 
ASMase-knockout HSCs. According to our 
observations in the knockout mice, complete 
absence of ASMase upregulates CtsB and CtsD. 
Since in previous studies we have already 
disclosed the importance of CtsB in liver fibrosis 
and that the use of a selective CtsB inhibitor 
(Ca074Me) reduced HSC activation in a 
experimental liver fibrosis model (10), we decided 
to test whether the upregulation of CtsB observed 
in ASMase-/- HSCs plays a causal role in their 
enhanced fibrogenic potential, evaluating the effect 
of inhibiting CtsB using the specific inhibitor 
Ca074Me. In analyzing the expression of α-SMA 
and Col1A1 in 7-day old HSC cultures, we 
observed an increased expression of these markers 
of HSC transdifferentiation that was prevented 
after Ca074Me treatment, both in wild-type and 
ASMase-/- HSCs (Fig. 2A). Moreover, proliferation 
was also significantly diminished under these 
conditions, even in ASMase-/- HSCs (Fig. 2B). As 
previously observed in wild-type HSCs (10), AKT 
phosphorylation induced by PDGF was enhanced 
in HSC from ASMase knockout mice and blocked 
by Ca074Me (not shown). Ca074Me did not cause 
any noticeable cell death or toxicity at the doses 
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and time utilized. Hence, these results suggest that 
CtsB is responsible for the enhanced fibrogenic 
features observed in ASMase knock-out HSCs.  
ASMase knockout mice exhibit increased 
liver fibrosis in response to CCl4 due to CtsB 
overexpression. Our previous studies indicated that 
heterozygous ASMase mice are less sensitive to in 
vivo liver fibrosis due to impaired CtsB activation. 
However, the preceding findings indicate that the 
complete loss of ASMase leads to increased CtsB 
expression, which is known to contribute to liver 
fibrosis and a marker of disease progression in 
NASH patients (17). Therefore, to analyze if CtsB 
overexpression sensitizes to liver fibrosis we 
decided to administer CCl4 to ASMase-/- and wild-
type mice. We chose CCl4 instead of bile duct 
ligation as the degree of liver damage is 
independent of ASMase (17). CCl4 challenge for 4 
weeks increased serum ALT levels in wild-type 
and ASMase deficient mice to a similar extent 
(Fig. 3A). As shown in Fig. 3B basal levels of 
CtsB activity were increased in ASMase-/- livers 
and were further enhanced upon induction of liver 
fibrosis with CCl4 only in ASMase deficient livers. 
In addition, enhanced levels of CtsD were also 
detected in ASMase deficient livers that were 
further increased after CCl4 challenge (Fig. 3C). 
Moreover, in CCl4-treated animals enhanced levels 
of CtsB and CtsD correlated with an elevated α-
SMA expression, as shown by western blot 
analysis (Fig. 3C) and immunohistochemistry (Fig. 
3D), indicating that ASMase deficient animals 
have increased number of activated HSCs. 
Analysis of the hydroxyproline content in the liver 
revealed a significant increase in collagen 
accumulation in ASMase deficient animals, 
compared to wild-type animals after CCl4 
administration (Fig. 3E), that correlated with the 
increased detection of collagen fibers in the livers 
of ASMase-/- mice that received CCl4, as detected 
by Sirius Red staining (Fig. 4A). The Sirius Red 
staining, as well as the α-SMA expression, 
observed in the ASMase-/- livers did not follow the 
typical pattern along the collagen fibers but display 
a characteristic arrangement surrounding foam 
cells, lipid-accumulating macrophages also known 
as Niemann-Pick cells. This atypical distribution 
was only observed in ASMase deficient livers that 
received CCl4, this particular cell type however 
was not observed in ASMase-/- animals receiving 
only vehicle (Fig. 4A). On histological 
examination we observed mild sinusoidal 
dilatation, by H&E staining (Fig. 4B), and 
moderate neutrophilic infiltration, as detected by 
myeloperoxidase immunostaining (Fig. 4C) in 
wild-type livers upon CCl4 challenge. These 
parameters were exacerbated in ASMase-/- animals 
that presented noticeable infiltration of 
neutrophiles especially adjacent to foam cells, 
clearly visible by H&E staining. Collectively these 
results indicate that liver fibrosis is significantly 
increased in ASMase-KO mice.  
CtsB inhibition reduces in vivo liver 
fibrosis in ASMase null mice. Given the above 
findings, as since CtsB inhibition has been proven 
useful in reversing liver fibrosis in wild-type mice 
(10), we next asked whether CtsB inhibition could 
be of relevance in ameliorating liver fibrogenesis 
in ASMase-/- livers in vivo following CCl4 
administration. To this aim, CCl4 was first 
administered twice a week for 1 week, followed by 
CCl4 and Ca074Me administration for 3 additional 
weeks. CtsB inhibition by itself did not alter any of 
the parameters studied in control animals (Fig. 3 
and Fig. 4). As previously described (10), 
Ca074Me treatment did not significantly affect the 
increase in ALT levels observed after CCl4 
challenge, suggesting that CtsB did not participate 
in the mechanisms responsible for liver damage 
(Fig. 3A). However, in vivo Ca074Me 
administration significantly reduced the increase in 
CtsB activity (approximately 30%) induced by 
CCl4 in ASMase-/- mice (Fig. 3B). Higher doses of 
Ca074Me failed to further inhibit CtsB activity in 
ASMase-/- mice (not shown). CtsB inhibition by 
Ca074Me reduced the increased expression of α-
SMA and CtsD (Fig. 3C), as well as the presence 
of α-SMA positive cells after CCl4 challenge in 
ASMase-/- livers (Fig 3D). Moreover, as shown in 
Fig. 3E, determination of the hydroxyproline 
content in the liver revealed a significant decrease 
in collagen accumulation in CCl4-treated mice that 
received Ca074Me, compared to mice challenged 
with CCl4 alone. This result was further confirmed 
by the detection of collagen fibers by Sirius Red 
staining (Fig. 4A) in CCl4-treated animals 
compared to those treated with CtsB inhibitor. 
Additionally, CtsB inhibition in CCl4-treated 
animals moderately decreased the incidence of 
foam cells in the liver (Fig. 4B) and the number of 
myeloperoxidase positive cells (Fig. 4C) Thus, 
these findings indicate that CtsB plays a critical 
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role in in vivo liver fibrogenesis in ASMase 
deficient livers. 
CtsB and D increase in extra hepatic 
organs in the ASMase knockout mice. To analyze 
whether the increase of CtsB and CtsD was an 
isolated feature of the liver from the ASMase-/- 
mice or was a general phenotypic characteristic in 
other organs, 21 weeks-old animals were 
euthanized, and different organs were harvested. 
CtsB (Fig. 5A) and CtsD (Fig. 5B) protein 
expression and activity increased in several organs 
affected by the accumulation of foam cells in NPD: 
brain, lung, liver, muscle, epididimal white adipose 
tissue (EWAT), and skin. However, there were no 
changes in spleen, pancreas, and intestine in those 
mice. When exploring the magnitude of ASMase 
and CtsB activities in the tissues of wild type 
animals we did not observe any direct correlation 
between the extent of activation of these two 
enzymes in view of the fact that tissues with the 
lowest ASMase activity, such as spleen and 
muscle, displayed respectively the highest and the 
lowest CtsB activities among the tissues examined 
(Fig. 5C). 
In order to analyze if the increase in CtsB 
was also detectable in younger animals with a 
weak NPD phenotype, 10-12 weeks-old mice were 
studied. Accumulation of foam cells was already 
detectable in histological sections of lung and 
liver, as well as a decrease in the number of 
Purkinje cells in the cerebellum (Fig. 6A), both 
characteristic of the neuro-visceral phenotype of 
the NPD. No changes were appreciated in spleen 
sections (data not shown). Interestingly, when 
enzymatic activity was measured in these almost 
asymptomatic young animals, CtsB was already 
significantly increased, in the lung and liver tissue 
from the ASMase knockout mice (Fig 6B), even 
despite the weak accumulation of foam cells in 
these tissues, which represents an early feature of 
the NPD phenotype. In contrast, no changes in 
CtsB activity were detected in brain and spleen at 
this age. 
Role of other cathepsins, lysosomal 
stability, and autophagy. To address the potential 
participation of other cathepsins in the NPD 
phenotype, we used a pan-cathepsin antibody with 
specificity towards several cathepsins other than 
CtsB/CtsD. As seen (Fig. 7A) the pattern of pan-
cathepsin expression between ASMase+/+ and 
ASMase-/- HSCs was similar. Moreover, while 
there were different patterns of expression among 
tissues, there were no major differences between 
ASMase+/+ and ASMase-/- mice (Fig 7B), except 
the observed enhanced pan-cathepsin expression in 
lung from ASMase-/- mice. Consequently, it is 
feasible that the participation of other cathepsins in 
NPD phenotype may be tissue specific. 
Given that an increase in cathepsins in the 
lysosome can lead to lysosomal membrane 
permeabilization and subsequent release of 
cathepsins leading to apoptosis (24), we next 
analyzed if lysosomal stability was affected and 
whether CtsB and CtsD were localized in the 
lysosomes of ASMase-/- HSC. As shown in Fig. 7A 
LAMP2 expression, known to correlate with 
lysosomal stability (25), was increased during HSC 
activation in ASMase-/- HSCs compared to 
ASMase+/+ HSCs at all time points analyzed, 
suggesting that in addition to increased CtsB and 
CtsD expression there seems to be enhanced 
lysosomal mass. LAMP2 expression was also 
enhanced in various tissues of ASMase-/- mice, 
particularly lung, liver and spleen (Fig. 7B). In 
agreement with these findings, 
immunofluorescence analyses of HSCs from wild 
type and ASMase null mice indicated 
colocalization of both CtsB and CtsD with 
LAMP2, a lysosomal marker (Fig 7C) and 
revealed increased LAMP2 staining in ASMase-/- 
HSCs compared to ASMase+/+ HSCs. However, no 
increase was observed in the expression of HSP70, 
a chaperone known to facilitate ASMase activity 
and stabilize lysosomes (26), neither in HSCs (Fig. 
7A) nor in the different tissues analyzed (Fig. 7B). 
Thus, these findings suggest that the increased 
CtsB expression in ASMase-/- HSCs may be due to 
lysosomal enlargement.  
Since autophagy is a catabolic process 
involving the degradation of cellular constituents 
through lysosomal digestion, we asked whether it 
played a role in HSCs activation and tissue 
degeneration in NPD. To address this point, we 
monitored LC3 expression in the different tissues 
of wild type and ASMase-/- mice. As shown in Fig. 
7B, the amount of LC3-I varied among tissues but 
remained constant between ASMase+/+ and 
ASMase-/- animals. There was, however, more 
expression of LC3-II in lung, intestine, EWAT and 
skin of ASMase-/- mice compared to ASMase+/+ 
mice. In addition, no expression of LC3-II was 
observed during HSC activation (Fig. 7A). 
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Therefore, no direct relationship was found 
between CtsB or CtsD expression (Fig. 5) and 
LC3-I conversion to LC3-II in the NPD mouse 
model. 
 
DISCUSSION 
NPD is a rare lysosomal disorder caused 
by the loss of ASMase. Patients with NPD exhibit 
neurodegeneration, lung dysfunction, 
hepatosplenomegaly and liver disease. While all 
lysosomal storage diseases are characterized by the 
intra-lysosomal accumulation of unmetabolized 
substrates, acting as a primary cause of the disease, 
the extensive range of disease symptoms indicates 
that many secondary biochemical and cellular 
pathways can contribute to the plethora of 
phenotypes reported (27). Currently, there is no 
treatment for NPD patients and the degree of 
pathology depends on the extent of ASMase loss. 
In the present study we extend our initial 
observations between ASMase and CtsB/D in HSC 
and liver fibrosis, which occurs in a large 
percentage of NPD patients (6). Heterozygous 
ASMase mice, which exhibit a residual 30-40% 
ASMase activity, are protected against in vivo liver 
fibrosis due to a decreased CtsB/D activation (17). 
Moreover pharmacological ASMase inhibition (by 
70-80%) decreased CtsB/D activation and the 
fibrogenic potential and proliferation of murine 
and human HSC. Quite surprisingly, we observe 
here that the genetic ablation of ASMase leads to a 
paradoxical increased basal level and activity of 
CtsB, which confers increased fibrogenic potential 
and proliferation on HSCs from ASMase null mice 
leading to enhanced liver fibrosis.  
Consistent with findings in death ligands-
induced apoptosis (15), our previous studies 
disclosed a hierarchical functional relationship 
between ASMase and CtsB of relevance in liver 
fibrosis (17). Unlike the pharmacological 
inhibition of ASMase, which impaired CtsB/D 
maturation and hence HSC activation, the 
inhibition of CtsB did not affect ASMase activity 
during in vitro HSC activation, indicating that 
ASMase is required for and upstream of CtsB/D 
proteolytic processing and that the gradual 
downregulation of ASMase, as in the heterozygous 
ASMase mice, results in impaired CtsB/D 
processing and activation. Although genetic CtsD 
silencing did reduce HSC proliferation and α-SMA 
expression in line with the effects observed with 
CtsB silencing, it did not affect HSC migration 
(10). Moreover, unlike CtsD, the expression of 
CtsB appears to be more restricted to activated 
HSC (10), suggesting that CtsB rather than CtsD 
may be a better target to address its role in liver 
fibrosis in NPD (10). Although, the present 
findings support a critical role for CtsB in hepatic 
fibrosis in NPD, we cannot rule out a potential 
contribution of other cathepsins, including CtsD. 
Due to the critical role of CtsB in liver 
fibrosis (10), the proportional direct relationship 
between the downregulation of ASMase and CtsB 
dictates a low susceptibility of the ASMase+/- mice 
to liver fibrosis (17). However, unexpectedly the 
loss of ASMase below a critical threshold towards 
the total deficiency of ASMase, as in the ASMase 
knockout mice, results in an adaptive increase in 
the basal levels of some cathepsins and enhanced 
proteolytic processing during HSC activation in 
vitro that sensitizes ASMase null mice to in vivo 
fibrosis. The unexpected rebound relationship 
between the loss of ASMase and activation of 
CtsB may be of particular relevance to type A but 
not type B NPD patients, which exhibit a residual 
ASMase activity. Pharmacological inhibition of 
CtsB decreases the in vitro activation of HSC from 
ASMase null mice and in vivo liver fibrosis, thus 
suggesting that targeting CtsB may be a novel 
treatment for the underlying liver fibrosis in NPD 
patients.  
Similar to the NPD phenotype, patients 
with Niemann-Pick type C1 (NPC1) disease 
caused by mutation in NPC1, an 
endosomal/lysosomal protein that regulates 
intracellular cholesterol trafficking, exhibit similar 
biochemical changes including free cholesterol, 
sphingolipids and bis-(monoacylglycerol) 
phosphate accumulation in intracellular 
compartments, including lysosomes and 
mitochondria from affected organs including brain 
and liver (28,29). Interestingly, similar to the 
findings presented in the current study, Amritaj et 
al described increased CtsB/D activity in neurons 
from the cerebellum of NPC1-/- mouse brain (30). 
 Consistent with the lack of neuronal 
degeneration in the hippocampus of NPC1-/- 
mouse, CtsB activation was not observed in this 
particular neuron population, thus establishing a 
correlation between increased CtsB activity and 
selective neurological dysfunction in NPC1 
disease. Our findings indicate that CtsB and CtsD 
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enhanced expression in the ASMase-/- mice are 
accompanied by an increase in lysosomal mass, 
but are probably not related to autophagy. Of note, 
while Hsp70 has been found to correlate not only 
with lysosomal stability but also to reverse NPD 
associated lysosomal pathology (31), we did not 
observe up-regulation of Hsp70 in ASMase-/- 
tissues. In line with our observations, studies in 
fibroblasts of NPC1 patients, or after treatment of 
normal fibroblasts with U18666A, a drug that 
reproduces the NPC1 phenotype by increasing free 
cholesterol accumulation in lysosomes, indicate 
that enhanced lysosomal cholesterol stimulates 
CtsD and LAMP2 expression, resulting in 
increased lysosomal stability and resistance to 
apoptosis (32). Moreover, these results were also 
independent of Hsp70 expression or autophagy. Of 
interest, secondary to ASMase deficiency there 
may be several associated changes in different 
tissues of ASMase null mice, including 
sphingolipids and cholesterol (33). However, 
unlike these data reported in 5 month-old ASMase 
null mice, our findings did not reveal any change 
in the hepatic cholesterol levels in 8-10 weeks old 
ASMase knockout mice (not shown), suggesting 
that the increase of hepatic cholesterol in the NPD 
mouse model may be age related, and that 
cholesterol plays a minor role in the increased 
susceptibility of ASMase null mice to hepatic 
fibrosis. Moreover, the protection against liver 
fibrosis afforded after CtsB inhibition appears to 
be independent on cholesterol changes.  
Our findings imply that liver fibrosis of 
NPD type A patients could be corrected by 
targeting a secondary associated enzyme, namely 
that the genetic cause of NPD type A liver disease 
due to the lack of ASMase, can be overcome by 
the inhibition of the adaptive increase in CtsB 
processing. Consistent with this concept, it has 
been shown that the phenotype defects observed in 
NPC1 disease, including free cholesterol 
accumulation and impaired transferring receptor 
recycling could be corrected by overexpressing 
ASMase, whose expression is also decreased in 
NPC1 disease (34). 
An important feature of the present study 
is that the upregulation of CtsB due to the lack of 
ASMase is not restricted to liver, but also observed 
in other affected organs, such as brain and lung, in 
an age dependent mechanism. Of relevance to the 
neurological phenotype there seems to be a 
threshold for ASMase activity below which these 
symptoms arise. For instance, it has been shown 
using mutation specific mouse models that as little 
as 8% ASMase activity can completely prevent the 
occurrence of neurological disease (35). In 
addition, while the residual ASMase activity of ~ 
5% results in NPD type B, however, a further 
reduction to ~1–2% or less induces the severe type 
A phenotype (36). These observations highlight the 
fact that although low levels of ASMase activity 
are sufficient to maintain intact neurological 
function, the absence of this activity has 
devastating consequences in the brain (37). 
Collectively, our results point to a new role 
for ASMase-CtsB axis in NPD. In addition to its 
known function as a pro-apoptotic intermediate in 
TNF or Fas-induced cell death (15,38), ASMase 
plays a critical role in regulating cathepsin 
processing and hence in modulating the diverse 
phenotypes of NPD including liver disease and 
neurological manifestations of the disease. Thus, 
targeting the increase in CtsB secondary to the loss 
of ASMase may be of relevance to NPD, 
particularly, for the fibrosis and liver disease 
phenotype of the disease. 
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FIGURE LEGENDS 
 
FIGURE 1. Enhanced fibrogenic potential of ASMase-/- HSC. (A) Time-course of CtsB, CtsD, and α-
SMA, and Col1A1 protein expression; (B) time-course of CtsB activity in ASMase+/+ and ASMase-/- 
HSCs; and time-course of (C) α-SMA, (D) Col1A1 and (E) TGF-β mRNA levels in ASMase-/- HSCs 
compared to ASMase+/+ HSCs. (F) Percentage of proliferation from day 2 to day 8 of culture in ASMase+/+ 
and ASMase-/- HSCs. Data are mean±SD, n=4 and *P≤ 0.01 vs. same-time point ASMase+/+ HSCs, **P≤ 
0.05 vs. control day 2 HSCs, and #P≤ 0.05 vs. ASMase+/+ HSCs.  
 
FIGURE 2. CtsB inhibition decreases the fibrogenic potential of HSCs. (A) α-SMA and Col1A1 protein 
levels, and (B) proliferation rate after CtsB inhibition with Ca074Me (20 µmol/L, 48 h, added every 24h 
from day 5 to day 7), in ASMase+/+, and ASMase-/-  HSCs. Data are mean±SD, n=3 and *P≤ 0.05 vs. 
ASMase+/+ control HSC; and #P≤ 0.05 vs. respective controls. 
 
FIGURE 3. Enhanced liver fibrosis in ASMase-/- mice after CCl4 administration was ameliorated after 
CtsB inhibition. (A) Serum ALT levels, (B) CtsB activity, (C) CtsD and α-SMA protein expression, (D) 
hydroxyproline levels in liver homogenate, and (E) α-SMA immunostaining of liver section at 40x 
magnification. Data are mean±SEM, n=6 animals per group and *P≤ 0.05 vs. vehicle-treated mice; and 
#P≤ 0.05 vs. CCl4 ASMase-/- treated mice. 
 
FIGURE 4. Fiber deposition, presence of foam cells and inflammation were decreased in ASMase-/- livers 
after CtsB inhibition. (A) Sirius Red staining of collagen fibers, (B) Hematoxylin & Eosin, and (C) 
myeloperoxidase (MPO) staining of liver sections after the corresponding treatments. All images were 
taken at 40x magnification. 
 
FIGURE 5. CtsB and CtsD increase in the organs affected by the NPD phenotype. (A) CtsB and (B) CtsD 
protein expression and activity in total lysates of brain, lung, spleen, liver, pancreas, intestine, EWAT, 
muscle, skin of  21-weeks old ASMase-/- and ASMase+/+ mice. (C) ASMase and CtsB activities in the 
same tissues of ASMase+/+ mice. In A and B, data are mean±SD, n=6 and *P≤ 0.05 vs. ASMase+/+. In C, 
n=4, *P≤ 0.05 vs. ASMase activity in liver, and #P≤ 0.05 vs. CtsB activity in liver of ASMase+/+ mice. 
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FIGURE 6. CtsB is increased in 10-12 weeks old animals with weak NPD phenotype. (A) Nissl staining 
in cerebellum histological sections and H&E staining of lung and liver sections. The arrows indicate the 
Purkinje cell population in cerebellum, population decreased in ASMase-/- mice, and the presence of foam 
cells in lung and liver in ASMase-/- mice. (B) CtsB activity in total lysates of brain, lung, spleen and liver 
of 10-12-weeks old ASMase-/- and ASMase+/+ mice. Data are mean±SD, n=3 and *P≤ 0.01 vs. ASMase+/+; 
and #P≤ 0.05 vs. ASMase+/+. 
 
FIGURE 7. Analysis of other cathepsins, lysosomal stability, and autophagy in the NPD mouse model. 
(A) Time course of pan-cathepsin, LAMP2, and LC3 expression in ASMase+/+ and ASMase-/- HSCs. (B) 
Pan-cathepsin, LAMP2, Hsp70 and LC3 expression in total lysates of brain, lung, spleen, liver, pancreas, 
intestine, EWAT, muscle, skin of  21-weeks old ASMase-/- and ASMase+/+ mice. (C) Confocal imaging of 
7 day-old ASMase+/+ and ASMase-/- HSCs displaying CtsB and CtsD co-localization with a lysosomal 
marker (LAMP2), Scale Bar = 10 µm. 
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